AptarGroup, Inc. (ATR)
NYSE:ATR
Want to see ATR full AI Analyst Report?
Top Page
AptarGroup
(NYSE:ATR)
Select Model
Select Model
Rating:55Neutral
Price Target:
$121.00
▼(-7.37% Downside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by elevated financial risk signals (TTM equity/leverage anomaly) and clear technical weakness (below major moving averages with negative momentum). Offsetting factors include steady profitability and cash generation, and an earnings outlook that anticipates sequential improvement despite notable near-term headwinds; valuation appears somewhat expensive with only a modest dividend.
Positive Factors
Recurring, diversified revenue model
Aptar’s core business sells proprietary dispensing and drug‑delivery components across healthcare, beauty and food. Pharma programs require engineering, regulatory-grade manufacturing and long qualification, creating multi-year commercial supply, recurring revenue and higher switching costs that support durable revenue visibility.
Negative Factors
TTM equity erosion and high leverage signal
Anomalously low TTM equity sharply increases leverage ratios and elevates refinancing, covenant and liquidity risks. Even with historically moderate annual leverage, a sustained erosion of equity reduces financial flexibility, raises interest sensitivity and constrains strategic options until capital structure is rebuilt.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring, diversified revenue model
Aptar’s core business sells proprietary dispensing and drug‑delivery components across healthcare, beauty and food. Pharma programs require engineering, regulatory-grade manufacturing and long qualification, creating multi-year commercial supply, recurring revenue and higher switching costs that support durable revenue visibility.
Read all positive factors
AptarGroup (ATR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.39B
Dividend Yield1.5%
Average Volume (3M)543.26K
Price to Earnings (P/E)19.2
Beta (1Y)0.57
Revenue Growth8.95%
EPS Growth6.13%
CountryUS
Employees13,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)5.91
Shares Outstanding63,820,316
10 Day Avg. Volume461,947
30 Day Avg. Volume543,257
Financial Highlights & Ratios
PEG Ratio3.60
Price to Book (P/B)3.01
Price to Sales (P/S)2.12
P/FCF Ratio26.76
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue2.22
Enterprise Value/Gross Profit7.64
Enterprise Value/Ebitda10.70
Forecast
1Y Price Target
$145.80Price Target Upside11.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)5.57
Revenue Forecast (FY)$3.98B
AptarGroup Business Overview & Revenue Model
Company Description
AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates t...
How the Company Makes Money
AptarGroup makes money primarily by manufacturing and selling proprietary dispensing, closure, and drug-delivery components to business customers (e.g., pharmaceutical companies and consumer packaged goods brand owners). Its revenue model is large...
AptarGroup Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: solid cash generation, product wins, meaningful pharma pipeline progress and targeted investments underpin medium-to-long-term growth. However, near-term headwinds—most notably a ~$65 million emergency medicine destock, margin compression across segments (Beauty and Closures), operational disruptions, and rising input costs—create tangible short-term pressure on profitability. Management expects sequential improvement and has provided a Q2 EPS range and full-year investment outlook, but near-term metrics reflect a mix of positive commercial momentum and notable operational and cost challenges.Positive Updates
Reported Sales Growth
Reported sales increased 11% year-over-year while core sales (adjusted for currency and acquisitions) were flat versus the prior year, indicating currency-driven reported growth and underlying stable demand.
Negative Updates
Core Sales and Prescription Weakness
Core sales were flat overall, with Pharma core sales down 1% and Prescription core sales down 10% year-over-year; emergency medicine destocking negatively impacted Pharma core sales by 3% in Q1.
Read all updates
Q1-2026 Updates
Positive
Negative
Reported Sales Growth
Reported sales increased 11% year-over-year while core sales (adjusted for currency and acquisitions) were flat versus the prior year, indicating currency-driven reported growth and underlying stable demand.
Read all positive updates
Company Guidance
Aptar guided Q2 adjusted EPS of $1.32–$1.40, an effective tax rate of 22.5%–24.5% and assumed EUR/USD of 1.18; for full‑year 2026 it expects capital investments of $260–$280 million and depreciation & amortization of $310–$320 million, while reiterating a previously disclosed ~$65 million emergency‑medicine sales decline (roughly two‑thirds hitting H1) and forecasting broad‑based segment growth with sequential margin improvement and the company remaining within its long‑term EBITDA margin target despite some percentage compression as higher raw‑material, transportation and energy costs are passed through to customers.AptarGroup Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
34
Negative
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.87B | 3.78B | 3.58B | 3.49B | 3.32B | 3.23B |
| Gross Profit | 1.12B | 1.12B | 1.36B | 1.26B | 1.16B | 1.16B |
| EBITDA | 801.82M | 799.70M | 777.45M | 663.84M | 609.41M | 586.79M |
| Net Income | 386.67M | 392.79M | 374.54M | 284.49M | 239.29M | 244.10M |
Balance Sheet | ||||||
| Total Assets | 5.10B | 5.25B | 4.43B | 4.45B | 4.20B | 4.14B |
| Cash, Cash Equivalents and Short-Term Investments | 229.48M | 409.53M | 226.18M | 223.64M | 141.73M | 123.67M |
| Total Debt | 1.41B | 1.53B | 1.08B | 1.18B | 1.22B | 1.24B |
| Total Liabilities | 2.42B | 2.54B | 1.95B | 2.13B | 2.14B | 2.16B |
| Stockholders Equity | 2.63B | 2.67B | 2.47B | 2.31B | 2.05B | 1.97B |
Cash Flow | ||||||
| Free Cash Flow | 325.47M | 299.58M | 349.22M | 256.84M | 163.00M | 55.51M |
| Operating Cash Flow | 605.95M | 570.00M | 643.41M | 575.24M | 478.62M | 363.44M |
| Investing Cash Flow | -339.10M | -330.64M | -396.72M | -324.46M | -295.64M | -457.24M |
| Financing Cash Flow | -173.82M | -78.26M | -225.34M | -171.55M | -162.10M | -81.52M |
AptarGroup Technical Analysis
Negative
130.63
Price Trends
122.74
Negative
126.90
Negative
126.83
Negative
Market Momentum
-2.44
Negative
39.86
Neutral
58.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATR, the sentiment is Negative. The current price of 130.63 is above the 20-day moving average (MA) of 117.87, above the 50-day MA of 122.74, and above the 200-day MA of 126.83, indicating a bearish trend. The MACD of -2.44 indicates Negative momentum. The RSI at 39.86 is Neutral, neither overbought nor oversold. The STOCH value of 58.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATR.
AptarGroup Risk Analysis
AptarGroup disclosed 28 risk factors in its most recent earnings report. AptarGroup reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AptarGroup Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $22.81B | 42.83 | 17.87% | 0.32% | 11.24% | 17.11% | |
65 Neutral | $11.94B | 30.00 | 4.83% | ― | 5.69% | -2.65% | |
65 Neutral | $5.09B | 30.99 | 9.63% | 0.29% | 15.54% | 21.77% | |
59 Neutral | $6.99B | 135.90 | 2.46% | ― | 17.36% | ― | |
55 Neutral | $7.39B | 19.19 | 14.33% | 1.50% | 8.95% | 6.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $9.70B | -8.81 | -16.43% | 2.75% | -4.79% | -78.01% |
* Healthcare Sector Average
ATR
AptarGroup
115.85
-38.83
-25.11%
BAX
Baxter International
18.78
-10.52
-35.90%
COO
Cooper Co
61.21
-5.79
-8.64%
RGEN
Repligen
123.95
5.38
4.54%
WST
West Pharmaceutical Services
322.81
114.11
54.68%
STVN
Stevanato Group
18.66
-3.20
-14.63%
AptarGroup Corporate Events
Executive/Board Changes
AptarGroup Appoints New Vice President and Chief Accounting Officer
Positive
May 13, 2026
On May 10, 2026, AptarGroup, Inc. announced the appointment of Aditya J. Gandhi as Vice President and Chief Accounting Officer, effective June 8, 2026, succeeding Daniel Ackerman, who has moved to another leadership role within the Aptar finance o...
Executive/Board Changes
AptarGroup Announces CEO Succession and Leadership Transition Plan
Positive
Mar 17, 2026
On March 16, 2026, AptarGroup announced that President and CEO Stephan Tanda will retire from his executive roles effective Sept. 1, 2026, with Aptar Pharma president Gael Touya appointed as his successor and expected to join the board at that tim...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.